Evidence map›Paper›PMID 37380021›Full record

ArticleContemporary clinical trials2023

Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study.

Stacey A Cohen, Susan Veleber, Jonathan Siman, Katherine A Guthrie, Kerry McMillen, Madilyn Heit, Sonia Wadhera, Jonathan Daniels, Kjell Hansen, Madeline Jacoby and 13 more

Open access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Regional limb cooling for the prevention of chemotherapy-induced toxicities: a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Stacey A CohenClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA. Electronic address: shiovitz@uw.edu.
Susan VeleberIntegrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA; Division of Public Health Sciences, Fred Hutchinson Cancer Center, USA.
Jonathan SimanIntegrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA; Division of Public Health Sciences, Fred Hutchinson Cancer Center, USA.
Katherine A GuthrieDivision of Public Health Sciences, Fred Hutchinson Cancer Center, USA.
Kerry McMillenClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA.
Madilyn HeitClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Sonia WadheraClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Jonathan DanielsClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Kjell HansenClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Madeline JacobyClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Katherine TarominaIntegrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA.
Samantha ChinIntegrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA.
Melissa RomeoIntegrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA.
Blake O LangleyIntegrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA; Division of Public Health Sciences, Fred Hutchinson Cancer Center, USA; Department of Child, Family, and Population Health Nursing, University of Washington, Seattle, WA 98195, USA.
Andrew L CovelerClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Lindsay M HannanDivision of Medical Oncology, University of Washington School of Medicine, USA.
Gentry KingClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Tom PurcellClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Rachael A SafyanClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Veena ShankaranClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
David B ZhenClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
E Gabriela ChioreanClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA.
Heather GreenleeClinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA; Division of Medical Oncology, University of Washington School of Medicine, USA; Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA; Division of Public Health Sciences, Fred Hutchinson Cancer Center, USA.
Fred Hutch Cancer Center · USUniversity of Washington Medical Center · US

Funding

Building Research across Interdisciplinary Gaps (BRIDG) R90 Training Program - Administrative SupplementR90AT008924 · NCCIH · NATIONAL UNIVERSITY OF NATURAL MEDICINE · PI BRADLEY, RYAN D, ZWICKEY, HEATHER LEA · 2015 to 2025
$5.2M
Building Research across Interdisciplinary Gaps (BRIDG) T90/R90 Training ProgramT90AT008544 · NCCIH · UNIVERSITY OF WASHINGTON · PI BOOTH-LAFORCE, CATHRYN, BRADLEY, RYAN D · 2015 to 2023
$3.9M
NCCIH NIH HHS R90 AT008924NCCIH NIH HHS T90 AT008544
6 · The paper itself

Abstract

backgroundOxaliplatin is a key chemotherapeutic agent in the treatment of local and metastatic gastrointestinal (GI) malignancies. Dose density and treatment adherence can be limited by chemotherapy-induced peripheral neuropathy (CIPN). Early research suggests CIPN incidence and severity may be mitigated by acupuncture, but rigorous data in GI oncology patients is limited. Here, we describe the protocol of a randomized, waitlist-controlled pilot study testing the use of preemptive of acupuncture plus acupressure to decrease CIPN and chemotherapy-related toxicities.

methodsPatients with a GI malignancy (n = 56) with planned 5-fluorouracil (5-FU) and oxaliplatin IV (FOLFOX, FOLFIRINOX) every 2 weeks are being recruited. Additional concurrent anti-neoplastic agents may be used. Enrolled patients are randomized 1:1 to a 3-month intervention of Arm A: acupuncture with acupressure and standard-of-care treatment, or Arm B: standard-of-care alone. In Arm A, on days 1 and 3 of each chemotherapy cycle a standardized acupuncture protocol is administered and patients are taught self-acupressure to perform daily between chemotherapy treatments. Patients in both arms are given standard-of-care oral and peripheral (hands/feet) ice chip cryotherapy during oxaliplatin administration. CIPN and other symptoms are assessed at baseline, 6 weeks, and 3 months from registration. The primary endpoint is CIPN severity at 3 months (EORTC-CIPN 20). Additional endpoints evaluate CIPN incidence (CTCAE, Neuropen, tuning fork); incidence of pain, fatigue, nausea, oral dysesthesia, and anxiety; and feasibility (recruitment, retention, adherence, acceptability). If warranted, trial results will inform the design of a multi-center trial to expand testing of the intervention to a larger patient cohort.

Indexed as

AcupressureAcupuncture TherapyAntineoplastic AgentsGastrointestinal NeoplasmsPancreatic NeoplasmsPeripheral Nervous System DiseasesAntineoplastic Combined Chemotherapy ProtocolsCryotherapyFeasibility StudiesHumansMulticenter Studies as TopicOxaliplatinRandomized Controlled Trials as TopicAntineoplastic AgentsOxaliplatinColorectal cancerOxaliplatinPancreatic cancerPeripheral neuropathy

Identifiers

PMID37380021
PMCPMC10527487
OpenAlexW4382051505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.